A novel type of therapeutic drugs which could be selectively activated by locally applied ultrasound is proposed to treat cancer and other disease. The technology is termed sonochemotherapy. The proposed sound excitable drugs (SED) are designed to have neither cytotoxicity nor phototoxicity in their native states, but having ultrasound inducible cytotoxicity. Ultrasound is a mature, safe and non-radiation technology, routinely used in various clinical imaging and treatments. Combining ultrasound with the proposed SED, the applied ultrasound wave could become a drug activator, converting non-toxic SED into cytotoxic agents to treat diseases at defined area. Different from conventional nonspecific chemotherapy, which has cytotoxic drugs circulating through out the body, sonochemotherapy provide site-specific chemotherapeutic effect. Ultrasound penetrates deep tissue emitting no radiation, thus the proposed sonochemotherapy is expected to become an alternative treatment approach of radiation therapy and photodynamic therapy with superior efficacy and safety.

Public Health Relevance

The goal of this research is to develop a new type of tunable chemotherapeutic agents which could only be activated by specific sound wave. The proposed sonochemotherapeutic technology is unique and could have great potential in cancer treatment. If successful, it could become a safe substitute to currently used radiation therapy.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1-GDB-7 (EU))
Program Officer
Okita, Richard T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Weill Medical College of Cornell University
Schools of Medicine
New York
United States
Zip Code
Tung, Ching-Hsuan; Han, Myung Shin; Kim, Young et al. (2017) Tumor ablation using low-intensity ultrasound and sound excitable drug. J Control Release 258:67-72
Pes, Lara; Kim, Young; Tung, Ching-Hsuan (2017) Bidentate iminodiacetate modified dendrimer for bone imaging. Bioorg Med Chem Lett 27:1252-1255
Zhang, Weiqi; Zhang, Zhe; Tung, Ching-Hsuan (2017) Beyond chemotherapeutics: cisplatin as a temporary buckle to fabricate drug-loaded nanogels. Chem Commun (Camb) 53:779-782
Tung, Ching-Hsuan; Qi, Jianjun; Hu, Lingchuan et al. (2015) A Quick Responsive Fluorogenic pH Probe for Ovarian Tumor Imaging. Theranostics 5:1166-74
Han, Junyan; Han, Myung Shin; Tung, Ching-Hsuan (2013) A non-toxic fluorogenic dye for mitochondria labeling. Biochim Biophys Acta 1830:5130-5
Han, Junyan; Han, Myung Shin; Tung, Ching-Hsuan (2013) A fluorogenic probe for ?-galactosidase activity imaging in living cells. Mol Biosyst 9:3001-8
Han, Junyan; Engler, Anthony; Qi, Jianjun et al. (2013) Ultra Pseudo-Stokes Shift Near Infrared Dyes Based on Energy Transfer. Tetrahedron Lett 54:502-505
Qi, Jianjun; Han, Myung Shin; Tung, Ching-Hsuan (2012) A benzothiazole alkyne fluorescent sensor for Cu detection in living cell. Bioorg Med Chem Lett 22:1747-9
Kim, Yoo-Shin; Rubio, Valentina; Qi, Jianjun et al. (2011) Cancer treatment using an optically inert Rose Bengal derivative combined with pulsed focused ultrasound. J Control Release 156:315-22
Qi, Jianjun; Tung, Ching-Hsuan (2011) Development of benzothiazole 'click-on' fluorogenic dyes. Bioorg Med Chem Lett 21:320-3

Showing the most recent 10 out of 11 publications